-
 Price Per Share potential
-
HEB chart
HEB wow what a great day for our members in the chat room Congrats to all.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
HEB pre market mover
4.40 pre market....wowza!!
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here
-
Profits
sold all mine @ $3.26 from 2.16 for 1500$ . Thank stockhide out and thanks mr1quan
-
 Get ready for another run monday!!!
Meanwhile, Hemispherx Biopharma's shares started the day on Friday as one of the top gainers, yet it ended up as the sector's biggest loser without any solid piece of bad news. Instead share prices were affected adversely after the company was hit twice the same day with negative opinion pieces from Street.Com's biotech columnist Adam Feuerst.
TWO POSITIVE DEVELOPMENT:
First, Reuters reported that Japan plans to produce enough H1N1 flu vaccine to treat 20 million people by the end of year. The company has been in discussions and testing their flu platforms with that country for quite some time.
“The highest level of the Japanese government and public medical community is now focused exclusively on our product,” Carter told BioMedReports last week. “They stopped working on all other adjuvants (boosters) and are only working with this one because they’ve found that it enhances the vaccines by 100 fold.”
Second, Prohost Biotechnology, an independent publication which evaluates biotechnology companies, their products, technologies, scientists and managers, as well as their finances for fund managers, investors, medical professionals issued a report on Friday calling both Hemispherx's Ampligen and Antigenics’(Nasdaq:AGEN) QS-21 Stimulon the two most indespenable vaccine adjuvants. "We need adjuvants and Ampligen is among those whom we really need to have available to infectious disease and oncology specialists" said the report.
Peer-reviewed medical publications, have reported key findings with a view to offering a rationale for the use of Ampligen as a potentially safe adjuvant- one recently published one from Cardiff Univeristy even summizes that the drug is capable of overcoming tumour-related immune tolerance mechanisms in a clinical setting.
The company is waiting for an approval decision for Ampligen's application to treat Chronic Fatigue Syndrome from the FDA. That decision should come on Tuesday, if not sooner according to previously released news.
We should see it back to $4.00 again!
-
Hemispherx Biopharma appoints Robert Dickey IV to the new position of
mpany/Investor Contact:
Dianne Will
Hemispherx Biopharma, Inc.
518-398-6222
ir@hemispherx.net
Hemispherx Biopharma appoints Robert Dickey IV to the new position of Senior Vice President
Role to facilitate strategic partnering and clinical progress
PHILADELPHIA, PA-June 17, 2009-Hemispherx Biopharma (NYSE AMEX: HEB) announced today the appointment of Robert Dickey IV as Senior
Vice President. This is a newly created role at Hemispherx that will bring together various activities relating to fund raising, strategic partnering
and finance functions. His role will also provide increased focus on strategic alliance evaluation and clinical project management, especially global
clinical programs.
Mr. Dickey combines over 12 years of experience in biotech senior management following an 18 year career as an investment banker. He has
been involved in three biotech companies holding positions including CFO, COO, CEO and board member. His experience spans startups to
revenue stage companies, fund raising, partnering and international operations. His experience further includes working in cancer and CNS drug
development, transplantation and computational drug design. As an investment banker, Mr. Dickey spent 14 years at Lehman Brothers in
various positions including Senior Vice President and four years at Legg Mason as a Managing Director. He has an undergraduate degree from
Princeton University and an MBA from the Wharton School of the University of Pennsylvania.
"Rob is coming on board at the most exciting point in our company's history and his breadth of background make a great fit," commented Dr.
William A. Carter, Chairman and CEO of Hemispherx. "We have a number of development programs under consideration relating to Ampligen®
and Alferon and will be very active in evaluating licensing opportunities."
"With the recent financings and the pending commercial opportunities Hemispherx is extremely well-positioned as compared to many other late
stage biotechs," Mr. Dickey said. "Moreover, given the recent progressive spread of pandemic flu there is a strategic imperative to accelerate
the Company's influenza programs and that will be an area of immediate focus for me. At the same time, we need to carefully look at all of our
opportunities, both internally and externally, and prioritize our activities."
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for
treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of
sexually transmitted diseases) and the experimental therapeutics, Ampligen® and Oragens. Ampligen® and Oragens represent experimental
RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform
technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases.
Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N
Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial
products. For more information please visit Hemispherx Biopharma, Inc. -- Research & Development: Welcome to our Website.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk
factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions,
change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with
the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company
(including Ampligen®, Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory
authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements
represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these
forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection® do not imply that the
product will ever be specifically approved commercially for these other treatment indications; similarly, the completion of the NDA filing process
with Ampligen® does not imply that the product will ever be approved commercially.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Re heb
HEB currently 2.46 in after hours trading. Next major resistance is the 20day MA line of 2.49 I know that we have several members in this stock. Good luck to all.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Re heb
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Re heb
Congrats to all who got back in on last nights alert +33% today Support is 2.96 and 2.85 There is some intraday resistance ahead but imo intaraday should be very week considering that the stock hasn't visited these levels since the first part of June I see no major resistance after todays high of 3.58 until 4.54
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
HEB video chart by TI
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks